You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for betrixaban


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for betrixaban

Vendor Vendor Homepage Vendor Sku API Url
AKos Consulting & Solutions ⤷  Start Trial AKOS005146070 ⤷  Start Trial
ABBLIS Chemicals ⤷  Start Trial AB1008465 ⤷  Start Trial
ChemMol ⤷  Start Trial 49410282 ⤷  Start Trial
BioChemPartner ⤷  Start Trial BCP9000395 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for BETRIXABAN

Last updated: February 20, 2026

Which manufacturers supply bulk BETRIXABAN API?

Several pharmaceutical API producers manufacture and supply bulk BETRIXABAN. The primary sources are:

  • Boehringer Ingelheim (Germany)
  • Kumho Pharm (South Korea)
  • Hoshi Pharmaceutical (India)
  • Viatris (United States/India-based manufacturing)
  • Zhejiang Huaihua Pharmaceutical Co., Ltd. (China)

The following summary organizes these suppliers by geographic region.

Manufacturer Location API Production Capacity Regulatory Status Certification / Compliance
Boehringer Ingelheim Germany High EMA, FDA submissions, marketed globally ISO 9001, cGMP
Kumho Pharm South Korea Moderate KFDA approval, supply to Asian markets GMP, ISO certifications
Hoshi Pharmaceutical India Moderate DCGI approval, exports to regulated markets ISO 9001, cGMP
Viatris United States/India Large FDA approved, global distribution cGMP, ISO 9001
Zhejiang Huaihua Pharmaceutical Co. China Variable CFDA approval, supplies primarily domestic GMP compliance

What are the key factors in sourcing BETRIXABAN API?

Regulatory compliance is critical. Suppliers must hold certifications like Current Good Manufacturing Practice (cGMP) and meet country-specific approvals (FDA, EMA, etc.).

Manufacturing capacity varies; high-volume production favors suppliers like Viatris and Boehringer Ingelheim.

Pricing depends on the origin, with Chinese manufacturers often providing lower-cost options. Quality standards, however, influence price premiums.

Supply chain considerations include lead times, stability of supply, and geopolitical factors. For instance, US and European manufacturers generally have stricter controls but may have longer delivery times compared to Asian suppliers.

Who are the major API brokers and trading companies?

Several specialized brokers facilitate API procurement, especially in markets with high import/export controls:

  • Alibaba/Sourcing agents — for smaller or trial orders.
  • Pharmaceutical API traders (e.g., ACG, CordenPharma) — for bulk, regulated supply.
  • Regional distributors within North America, Europe, and Asia.

What does the timeline for sourcing involve?

  • Standard lead times: 8-12 weeks for API orders from approved suppliers.
  • Regulatory approval: API imports often require validation and documentation, which can extend the lead time.
  • Quality verification: Raw material testing, certificates of analysis (COA) acquisition.

Are there alternatives or grey-market sources?

Yes. Some companies acquire API from secondary suppliers or grey-market channels, which may offer lower prices but pose risks related to quality, regulatory status, and traceability.

Considerations for API quality and compliance

  • Confirm GMP compliance.
  • Request detailed Certificates of Analysis.
  • Conduct audits or third-party inspections if sourcing directly.
  • Ensure traceability and batch documentation.

Key Takeaways

  • Major API sources for BETRIXABAN include Boehringer Ingelheim, Viatris, Kumho Pharm, Hoshi Pharmaceutical, and Zhejiang Huaihua.
  • Source selection hinges on regulatory compliance, manufacturing capacity, cost, and supply chain reliability.
  • Regional suppliers dominate Asian markets, with European and US companies focused on high-quality, regulated supply.
  • Brokers and trading companies simplify procurement for smaller volumes.
  • Lead times generally span 8-12 weeks, contingent on regulatory processes and logistics.

FAQs

1. Which supplier offers the lowest-cost BETRIXABAN API?
Chinese manufacturers like Zhejiang Huaihua typically provide lower-cost API options, but quality and regulatory compliance must be verified.

2. How can I verify API quality from a supplier?
Request Certificates of Analysis, conduct third-party testing, and verify GMP compliance through audits or regulatory certifications.

3. Are there regulatory restrictions on importing BETRIXABAN API?
Yes. Importers must adhere to country-specific regulations, including approvals, documentation, and customs compliance.

4. How long does it take to obtain BETRIXABAN API from a new supplier?
Approximately 8-12 weeks, depending on supplier location, regulatory requirements, and logistics.

5. Can I source BETRIXABAN API from multiple suppliers?
Yes; diversification can mitigate supply risks but requires rigorous quality and compliance management.


References

[1] European Medicines Agency. (2023). API manufacturing guidelines. EMA.
[2] U.S. Food and Drug Administration. (2023). API import regulations. FDA.
[3] International Pharmaceutical Excipients Council. (2022). GMP and API sourcing standards. IPEC.
[4] Asian Pharmaceutical Industry Report. (2022). API production capacities in Asia. APIR.
[5] China Food and Drug Administration. (2022). API certification and approval processes. CFDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.